Karolina Piotrowicz1,2, Anna Głuszewska1,2, Joanna Czesak2,3, Małgorzata Fedyk-Łukasik1,2, Ewa Klimek1,2, Dolores Sánchez-Rodríguez4,5, Anna Skalska1,2, Barbara Gryglewska1,2, Tomasz Grodzicki1,2, Jerzy Gąsowski6,7. 1. Department of Internal Medicine and Gerontology, Faculty of Medicine, Medical College, Jagiellonian University, Ul. Jakubowskiego 2, 30-688, Kraków, Poland. 2. Department of Internal Medicine and Geriatrics, University Hospital, Kraków, Poland. 3. Department of Clinical Rehabilitation, University School of Physical Education, Kraków, Poland. 4. Division of Public Health, Epidemiology and Health Economics, WHO Collaborating Centre for Public Health Aspects of Musculo-Skeletal Health and Ageing, University of Liège, Liège, Belgium. 5. Geriatrics Department, Rehabilitation Research Group, Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain. 6. Department of Internal Medicine and Gerontology, Faculty of Medicine, Medical College, Jagiellonian University, Ul. Jakubowskiego 2, 30-688, Kraków, Poland. jerzy.gasowski@uj.edu.pl. 7. Department of Internal Medicine and Geriatrics, University Hospital, Kraków, Poland. jerzy.gasowski@uj.edu.pl.
Abstract
BACKGROUND: Sarcopenia is a potentially reversible condition, which requires proper screening and diagnosis. AIMS: To validate a Polish version of sarcopenia screening questionnaire (SARC-F), and assess its clinical performance. METHODS: Cross-sectional validation study in community-dwelling subjects ≥ 65 years of age. Diagnosis of sarcopenia was based on the 2018 2nd European Working Group on Sarcopenia in Older People (EWGSOP2) consensus. Hand grip and 4-m gait speed were measured, and the Polish version of SARC-F was administered. RESULTS: The mean (SD) age of 73 participants (21.9% men) was 77.8 (7.3) years. Seventeen participants (23.3%) fulfilled the EWGSOP2 criteria of sarcopenia, and 9 (12.3%) criteria for severe sarcopenia. Fourteen (19.2%) participants fulfilled the SARC-F criteria for clinical suspicion of sarcopenia. The Cronbach's alpha coefficient for internal was 0.84. With EWGSOP2 sarcopenia as a gold standard, the sensitivity of SARC-F was 35.3% (95% CI 14.2-61.7, p = 0.33), specificity was 85.7% (95% CI 73.8-93.6, p < 0.0001). The corresponding positive and negative predictive values were 42.9% (p = 0.79) and 81.4% (p < 0.0001), respectively. The probability of false-positive result was 14.3% (95% CI 6.4-26.2, p < 0.0001) and the probability of false-negative result was 64.7% (95% CI 38.3-85.8, p = 0.33). Overall the predictive power of SARC-F was low (c-statistic 0.64). DISCUSSION: SARC-F is currently recommended for sarcopenia case finding in general population of older adults. However, its sensitivity is low, despite high specificity. CONCLUSIONS: At present SARC-F is better suited to rule out sarcopenia then to case-finding. Further refinement of screening for sarcopenia with the use of SARC-F seems needed.
BACKGROUND:Sarcopenia is a potentially reversible condition, which requires proper screening and diagnosis. AIMS: To validate a Polish version of sarcopenia screening questionnaire (SARC-F), and assess its clinical performance. METHODS: Cross-sectional validation study in community-dwelling subjects ≥ 65 years of age. Diagnosis of sarcopenia was based on the 2018 2nd European Working Group on Sarcopenia in Older People (EWGSOP2) consensus. Hand grip and 4-m gait speed were measured, and the Polish version of SARC-F was administered. RESULTS: The mean (SD) age of 73 participants (21.9% men) was 77.8 (7.3) years. Seventeen participants (23.3%) fulfilled the EWGSOP2 criteria of sarcopenia, and 9 (12.3%) criteria for severe sarcopenia. Fourteen (19.2%) participants fulfilled the SARC-F criteria for clinical suspicion of sarcopenia. The Cronbach's alpha coefficient for internal was 0.84. With EWGSOP2 sarcopenia as a gold standard, the sensitivity of SARC-F was 35.3% (95% CI 14.2-61.7, p = 0.33), specificity was 85.7% (95% CI 73.8-93.6, p < 0.0001). The corresponding positive and negative predictive values were 42.9% (p = 0.79) and 81.4% (p < 0.0001), respectively. The probability of false-positive result was 14.3% (95% CI 6.4-26.2, p < 0.0001) and the probability of false-negative result was 64.7% (95% CI 38.3-85.8, p = 0.33). Overall the predictive power of SARC-F was low (c-statistic 0.64). DISCUSSION: SARC-F is currently recommended for sarcopenia case finding in general population of older adults. However, its sensitivity is low, despite high specificity. CONCLUSIONS: At present SARC-F is better suited to rule out sarcopenia then to case-finding. Further refinement of screening for sarcopenia with the use of SARC-F seems needed.
Authors: René Rizzoli; Jean-Yves Reginster; Jean-François Arnal; Ivan Bautmans; Charlotte Beaudart; Heike Bischoff-Ferrari; Emmanuel Biver; Steven Boonen; Maria-Luisa Brandi; Arkadi Chines; Cyrus Cooper; Sol Epstein; Roger A Fielding; Bret Goodpaster; John A Kanis; Jean-Marc Kaufman; Andrea Laslop; Vincenzo Malafarina; Leocadio Rodriguez Mañas; Bruce H Mitlak; Richard O Oreffo; Jean Petermans; Kieran Reid; Yves Rolland; Avan Aihie Sayer; Yannis Tsouderos; Marjolein Visser; Olivier Bruyère Journal: Calcif Tissue Int Date: 2013-07-05 Impact factor: 4.333
Authors: A J Mayhew; K Amog; S Phillips; G Parise; P D McNicholas; R J de Souza; L Thabane; P Raina Journal: Age Ageing Date: 2019-01-01 Impact factor: 10.668
Authors: Jacob Pacifico; Milou A J Geerlings; Esmee M Reijnierse; Christina Phassouliotis; Wen Kwang Lim; Andrea B Maier Journal: Exp Gerontol Date: 2019-12-28 Impact factor: 4.032
Authors: Charlotte Beaudart; Eugène McCloskey; Olivier Bruyère; Matteo Cesari; Yves Rolland; René Rizzoli; Islène Araujo de Carvalho; Jotheeswaran Amuthavalli Thiyagarajan; Ivan Bautmans; Marie-Claude Bertière; Maria Luisa Brandi; Nasser M Al-Daghri; Nansa Burlet; Etienne Cavalier; Francesca Cerreta; Antonio Cherubini; Roger Fielding; Evelien Gielen; Francesco Landi; Jean Petermans; Jean-Yves Reginster; Marjolein Visser; John Kanis; Cyrus Cooper Journal: BMC Geriatr Date: 2016-10-05 Impact factor: 3.921
Authors: Alfonso J Cruz-Jentoft; Gülistan Bahat; Jürgen Bauer; Yves Boirie; Olivier Bruyère; Tommy Cederholm; Cyrus Cooper; Francesco Landi; Yves Rolland; Avan Aihie Sayer; Stéphane M Schneider; Cornel C Sieber; Eva Topinkova; Maurits Vandewoude; Marjolein Visser; Mauro Zamboni Journal: Age Ageing Date: 2019-01-01 Impact factor: 10.668
Authors: Juergen Bauer; John E Morley; Annemie M W J Schols; Luigi Ferrucci; Alfonso J Cruz-Jentoft; Elsa Dent; Vickie E Baracos; Jeffrey A Crawford; Wolfram Doehner; Steven B Heymsfield; Aminah Jatoi; Kamyar Kalantar-Zadeh; Mitja Lainscak; Francesco Landi; Alessandro Laviano; Michelangelo Mancuso; Maurizio Muscaritoli; Carla M Prado; Florian Strasser; Stephan von Haehling; Andrew J S Coats; Stefan D Anker Journal: J Cachexia Sarcopenia Muscle Date: 2019-09-15 Impact factor: 12.910